Literature DB >> 26271794

Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma.

Yanli Xiong1, Jia Liu, Shu Chen, Qian Zhou, Wenjing Xu, Chen Tang, Yonghong Chen, Mei Yang, Xin Lei.   

Abstract

The objective of this study was to compare the effect of combined external beam radiotherapy (EBRT) and Californium (Cf)-252 neutron intracavity brachytherapy (ICBT) on cervical squamous versus adenocarcinoma. A total of 106 patients with stage IB-IIIB cervical cancer were accrued between January 2005 and May 2011 and divided into squamous cell carcinoma (SCC) and adenocarcinoma (AC) as a pair with 53 patients in each group according to tumor size, stage, age, and hemoglobin level using matched-pair design. The whole pelvic EBRT was performed with 2 Gy/fraction, 4 fractions/week. The total dose was 48-54 Gy (the center of whole pelvic field was blocked by 4 cm in width after 20-36 Gy). Cf-252 neutron ICBT was delivered with 11 and 12 Gy-eq/f with the total dose at point A of 44 and 48 Gy-eq for SCC and AC patients, respectively. The mean follow-up time was 43 months. The 5-year LC, OS, DFS, LAC rates, and mean survival time were 66.0, 56.6, 52.8.0, 17.0%, and 76.4 ± 6.2 months, respectively, for AC patients, whereas they were 81.1, 69.8, 67.9, 11.3%, and 93.3 ± 4.3 months, respectively, for SCC patients. Furthermore, the early treatment toxicity was mild in both groups, the late treatment complications were mainly radiation-induced proctitis and cystitis, and there were no grade 3 or higher complications. Although the combination of Cf-252 neutron ICBT and EBRT was effective in both histology types of cervical cancer, a more aggressive strategy is needed to control cervical AC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26271794     DOI: 10.1007/s12032-015-0670-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  30 in total

1.  Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma.

Authors:  Seiji Mabuchi; Mika Okazawa; Koji Matsuo; Mahiru Kawano; Osamu Suzuki; Takashi Miyatake; Takayuki Enomoto; Shoji Kamiura; Kazuhiko Ogawa; Tadashi Kimura
Journal:  Gynecol Oncol       Date:  2012-06-21       Impact factor: 5.482

Review 2.  Adenocarcinoma: a unique cervical cancer.

Authors:  Lilian T Gien; Marie-Claude Beauchemin; Gillian Thomas
Journal:  Gynecol Oncol       Date:  2009-10-31       Impact factor: 5.482

3.  Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer.

Authors:  Kanyarat Katanyoo; Sompol Sanguanrungsirikul; Sumonmal Manusirivithaya
Journal:  Gynecol Oncol       Date:  2012-01-28       Impact factor: 5.482

4.  Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia.

Authors:  Takashi Nakano; Yoshiyuki Suzuki; Tatsuya Ohno; Shingo Kato; Michiya Suzuki; Shinroku Morita; Shinichiro Sato; Kuniyuki Oka; Hirohiko Tsujii
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

5.  Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma.

Authors:  Li Gong; Wen-Dong Zhang; Xiao-Yan Liu; Xiu-Juan Han; Li Yao; Shao-Jun Zhu; Miao Lan; Yan-Hong Li; Wei Zhang
Journal:  Diagn Pathol       Date:  2010-04-24       Impact factor: 2.644

6.  Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma.

Authors:  Jayanthi S Lea; Robert L Coleman; Elizabeth O Garner; Linda R Duska; David S Miller; John O Schorge
Journal:  Gynecol Oncol       Date:  2003-12       Impact factor: 5.482

7.  Californium-252 (252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma long-term treatment results of a randomized study.

Authors:  Taco Tacev; Blanka Ptácková; Vratislav Strnad
Journal:  Strahlenther Onkol       Date:  2003-06       Impact factor: 3.621

8.  Phase II clinical trial using californium 252 fast neutron brachytherapy, external pelvic radiation, and extrafascial hysterectomy in the treatment of bulky, barrel-shaped stage IB cervical cancer.

Authors:  J R van Nagell; Y Maruyama; E S Donaldson; M B Hanson; H H Gallion; J Yoneda; D E Powell; R J Kryscio; J L Beach
Journal:  Cancer       Date:  1986-05-15       Impact factor: 6.860

9.  Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix?

Authors:  H M Shingleton; M C Bell; A Fremgen; J S Chmiel; A H Russell; W B Jones; D P Winchester; R E Clive
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

10.  Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy.

Authors:  Jenny Ling-Yu Chen; Chao-Yuan Huang; Yu-Sen Huang; Ruey-Jien Chen; Chun-Wei Wang; Yu-Hsuan Chen; Jason Chia-Hsien Cheng; Ann-Lii Cheng; Sung-Hsin Kuo
Journal:  Acta Obstet Gynecol Scand       Date:  2014-04-22       Impact factor: 3.636

View more
  3 in total

1.  Californium-252 neutron intracavity brachytherapy alone for T1N0 low-lying rectal adenocarcinoma: A definitive anal sphincter-preserving radiotherapy.

Authors:  Yanli Xiong; Jinlu Shan; Jia Liu; Kewei Zhao; Shu Chen; Wenjing Xu; Qian Zhou; Mei Yang; Xin Lei
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

2.  Clinicopathological characteristics and prognostic factors of cervical adenocarcinoma.

Authors:  Min Wang; Bo Yuan; Zhen-Huan Zhou; Wei-Wei Han
Journal:  Sci Rep       Date:  2021-04-05       Impact factor: 4.379

3.  Prognostic factors for IB2-IIIB cervical cancer patients treated by radiation therapy with high-dose-rate brachytherapy in a single-institution study.

Authors:  Yu-Ting Xiu; Fan-Xu Meng; Zhuo Wang; Kang-Kang Zhao; Yun-Long Wang; Zhi-Shen Chen; Bao-Sheng Sun
Journal:  J Contemp Brachytherapy       Date:  2022-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.